Drug Type Autologous CAR-T |
Synonyms Anti-CD19 CAR-T cells therapy(Tianjin Mycure Medical Technology), CD19 CAR-T cells(Tianjin Mycure Medical Technology) |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | China | 07 Sep 2018 | |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 07 Sep 2018 |





